AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ANALYSIS

Automated Antimicrobial Susceptibility Testing Market, By Product Type (Consumables and Instruments), By Detection Method (Turbidimetric and Colorimetric), By Application (Antibacterial (Tuberculosis and Sepsis), Antifungal, Anti-parasitic, and Anti-viral), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Hospitals, and Pathology/Diagnostic Laboratories), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Published In : May 2019
Code : CMI2622
Pages :200
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Regional Analysis

Automated Antimicrobial Susceptibility Testing Market - Regional Insights

On the basis of region, the global automated antimicrobial susceptibility testing market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global automated antimicrobial susceptibility testing market during the forecast period, owing to development of new antimicrobial testing procedures and increasing awareness among people regarding antimicrobial resistance (AMR). For instance, in April 2018, the U.S. Food and Drug Administration approved Thermo Scientific Sensititre ID/AST System, the first to offer delafloxacin and meropenem/vaborbactam on IVD-labeled, microbroth dilution susceptibility plates. The antimicrobials are currently available in the U.S. on Sensititre custom plates and are expected be available soon in new standard formats.

Asia Pacific is expected to witness rapid growth in the automated antimicrobial susceptibility testing market, owing to high prevalence of microbial infections and increasing consumption of antibiotics, eventually developing resistance among the population. For instance, according to a 2014 WHO report, multidrug-resistant tuberculosis rates were high in India, especially among those who were previously treated and treatment for the disease is generally limited.